Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia.
No Thumbnail Available
Date
1989-12-01
Authors
Jootar, S
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Four patients with chronic myelogenous leukemia and thrombocytosis and one patient with essential thrombocythemia were treated with purified recombinant human interferon alpha-2a (IFN-alpha 2a). Significant decline in platelet counts, from a mean ( +/- SE) of 1.396 +/- 0.265 x 10(6)/mm3 to a mean of 0.396 +/- 0.04 x 10(6)/mm3 (p less than 0.05), was observed in all patients. The platelet count remained normal for 15, 21 and 30 days after discontinuation of IFN-alpha 2a in 3 patients. In 2 patients the platelet count began to rise slowly two weeks after discontinuation of IFN-alpha 2a. Our preliminary observations suggest that purified recombinant human IFN-alpha 2a may effectively control progressive thrombocytosis in advanced chronic myelogenous leukemia and essential thrombocythemia.
Description
Published by the Allergy and Immunology Society of Thailand.
Keywords
Citation
Jootar S. Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia. Asian Pacific Journal of Allergy and Immunology. 1989 Dec; 7(2): 103-5